Long term azithromycin therapy in patients with cystic fibrosis
Long term azithromycin therapy in patients with cystic fibrosis
About this item
Full title
Author / Creator
Publisher
Turkey: Hacettepe University Faculty of Medicine
Journal title
Language
English
Formats
Publication information
Publisher
Turkey: Hacettepe University Faculty of Medicine
Subjects
More information
Scope and Contents
Contents
Inflammation is a central contributor to the pathogenesis of cystic fibrosis (CF) pulmonary disease; so limiting the excessive production of inflammatory mediators represents a major therapeutic strategy for slowing the decline in lung function and improving survival. The macrolide antibiotic azithromycin (AZM) has anti-inflammatory properties and...
Alternative Titles
Full title
Long term azithromycin therapy in patients with cystic fibrosis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_df0a3355eb004aac89327fa2d0ae116d
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_df0a3355eb004aac89327fa2d0ae116d
Other Identifiers
ISSN
0041-4301
E-ISSN
2791-6421
DOI
10.24953/turkjped.2016.01.005
